22.60

3.95% -0.93

Pharvaris NV (PHVS)

Overview News Price History Discussions Forecast

Pharvaris NV stock is currently priced at $22.60, with a 24-hour trading volume of 55,488. It has seen a -3.95% decreased in the last 24 hours and a +1.39% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $24.17 pivot point. If it approaches the $22.16 support level, significant changes may occur.

Previous Close:

$23.53

Open:

$23.77

24h Volume:

55,488

Market Cap:

$1.22B

Revenue:

Net Income/Loss:

$-84.47M

P/E Ratio:

-10.57

EPS:

-2.138

Net Cash Flow:

$-100.83M

1W Performance:

-3.21%

1M Performance:

+1.39%

6M Performance:

+22.29%

1Y Performance:

+155.08%

1D Range:

$22.48

$23.90

52W Range:

$7.93

$33.00

Pharvaris NV Stock (PHVS) Company Profile

Name

Pharvaris NV

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

31 71 203 6410

Address

J.H. Oortweg 21, Leiden

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

PHVS's Discussions on Twitter

Pharvaris NV Stock (PHVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-25-23	Initiated	Wedbush	Outperform
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-05-22	Initiated	Bryan Garnier	Buy
Sep-13-22	Resumed	JMP Securities	Mkt Outperform
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform
May-25-22	Initiated	JMP Securities	Mkt Outperform
Mar-02-21	Initiated	BofA Securities	Neutral
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	SVB Leerink	Outperform

View All

Pharvaris NV Stock (PHVS) Latest News

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

GlobeNewswire Inc.

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

GlobeNewswire Inc.

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

GlobeNewswire Inc.

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

GlobeNewswire Inc.

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

GlobeNewswire Inc.

Pharvaris NV Stock (PHVS) Financials Data

Pharvaris NV (PHVS) Net Income 2024

PHVS net income (TTM) was -$84.47 million for the quarter ending December 31, 2023, a -5.51% decrease year-over-year.

Pharvaris NV (PHVS) Cash Flow 2024

PHVS recorded a free cash flow (TTM) of -$100.83 million for the quarter ending December 31, 2023, a -42.10% decrease year-over-year.

Pharvaris NV (PHVS) Earnings per Share 2024

PHVS earnings per share (TTM) was -$2.15 for the quarter ending December 31, 2023, a +9.72% growth year-over-year.

Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.